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Summary 
Introduction 
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a dangerous complication 
of bisphosphonates, a class of pharmaceutical agents used in numerous bone disor-
ders. 
No gold standard therapy exists, but recent literature suggests that, in advanced 
stages, the best results are achieved with aggressive debridement. 
In this paper, we report our experience of treatment of stage 3 BRONJ of the maxilla 
with extensive surgical debridement and reconstruction with a chimeric ALT-Vastus 
lateralis flap. 
Methods 
Five selected patients with stage 3 BRONJ underwent partial maxillectomy with dis-
ease-free margins followed by immediate reconstruction with a chimeric ALT-Vastus 
lateralis free flap. 
Results 
Only two patients experienced minor complications. All other patients healed unevent-
fully within two weeks and donor site morbidity was minimal. 
Conclusions 
Our data suggest that aggressive debridement and reconstruction with a chimeric ALT
-Vastus lateralis flap is an effective option for the treatment of stage III BRONJ of the 
maxilla. 
Introduction 
Bisphosphonate related osteonecrosis of the jaw (BRONJ) is defined as the presence 
of exposed bone in the oral cavity that does not regress within eight weeks in a pa-
tient who is currently, or has previously been, treated with bisphosphonates and who 
has not had radiotherapy to the craniofacial region1. 
It is a relatively rare but potentially dan-
gerous complication of treatment with 
bisphosphonates2, a class of pharmaceu-
tical agents used in numerous bone dis-
orders, including osteoporosis, bone me-
tastases, and multiple myeloma.  
The exact pathogenetic mechanism of 
BRONJ has still to be established, but it 
is clear that infection, trauma and re-
duced vascularity play important roles3,4. 
The most commonly reported initiating 
factor for BRONJ, in fact, is tooth extrac-
tion, although periodontal disease and 
damage caused by dentures have also 
been implicated5,6. 
Bishosponates inhibit bone turnover, 
stimulating osteoclastic apoptosis and 
constrasting osteoblast-mediated osteo-
clastic activity and neoangiogenesis2,7-9. 
Thus, the jaws are most frequently af-
fected because of their high turnover.  
BRONJ is usually staged according to the 
following classifications3: 
 stage 1: asymptomatic bone expo-
sure; 
 stage 2: painful bone exposure due to 
concurrent infection at the level of the 
exposed bone; 
 stage 3: complicated cases with ex-
traoral fistulae and fractures. 
Mawardi et al. defined ‘‘stage 0’’ or ‘‘non-
exposed BRONJ’’ as an early stage with-
out exposed bone10. This definition has 
also been incorporated among the 
AAOMS BRONJ diagnostic criteria3. Wilde 
et al.11 distinguished advanced disease in 
stage 3 (exposed necrotic bone associ-
ated with pain, infection with swelling 
and abscesses, multiple intraoral fistulas, 
and extended osteolysis in the radiologic 
findings) and stage 4 (exposed necrotic 
bone associated with pain, infection with 
swelling and abscesses, pathologic frac-
ture, naso-oral fistula, extraoral fistula, 
or osteolysis extending to the inferior 
border). Begogni et al.12 proposed a dif-
ferent three stage classification as an 
alternative to the AAOMS classification:  
- stage 1: focal (alveolar bone) osteo-
sclerosis; 
- stage 2: diffuse (alveolar and basal 
bone) osteosclerosis; 
- stage 3: clinical and radiological signs 
of advanced and complicated disease. 
They do not include a stage 0, with the 
idea that BRONJ patients with exposed 
and non-exposed necrotic bone simply 
represent distinct clinical pictures within 
the same disease stage. Pain and puru-
lent discharge are no longer used to dis-
tinguish between different disease 
stages, but only between asymptomatic 
(a) and symptomatic (b) forms of BRONJ. 
While there is no consensus yet on the 
gold standard therapy for BRONJ, recent 
literature suggests that, differently from 
early stages, in advanced stages the best 
results are achieved with aggressive de-
bridement3,13-15and subsequent recon-
struction. 
In this paper, we report our experience 
on the treatment of stage 3 BRONJ of the 
maxilla with extensive bone resection 
and reconstruction with a chimeric ALT-
Vastus lateralis flap. 
 
Methods 
From 2008 to 2013, five patients with 
stage 3 BRONJ (figure 1) were surgically 
treated at a single center. Two were male 
and three were female. Mean age was 63 
years old (range: 49-69). In all cases the 
osteonecrosis was localized in the max-
illa. No patients had any history of head 
and neck malignancy or radiation ther-
apy. Indications for bisphosphonates 
therapy were breast carcinoma in three 
cases, lung carcinoma in one case, and 
prostatic carcinoma in one case.  Dura-
tion of therapy ranged from nine to 42 
months (mean: 23) (table 1). 
All patients received peri- and post-
operative antibiotic treatment. 
All patients underwent a partial maxillec-
tomy with disease-free margins followed 
by immediate reconstruction with a chi-
meric ALT-Vastus lateralis free flap 
(figure 2). Resection was not limited to 
resection of the necrotic bone, but en-
tailed aggressive debridement up to the 
visualization of healthy bleeding bone.  
Mean follow up was 13 months (range: 6
-24). Healing time, postoperative compli-
cations and BRONJ recurrence were as-
sessed. Recipient and donor site out-
comes were evaluated.   
 
Results 
All patients healed uneventfully within 
two weeks, with the exception of a 
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Table 1: Patients’ data on BRONJ diagnosis and treatment  
Figure 1: Preoperative view of a 65 years old female patient with a stage 3 BRONJ 
of the maxilla 
 PATIENT SEX/AGE STAGE 
INDICATION FOR 
BISPHOSPHONATES 
THERAPY 
COMPLICATIONS 
1 F/69 III Breast cancer None 
2 F/65 III Breast cancer None 
3 F/49 III Breast cancer Flap dehiscence  
4 M/64 III Lung cancer None 
5 M/68 III Prostatic cancer None 
Figure 2: A. Preoperative view of a 64 years old male patient with a stage 3 BRONJ 
of the maxilla. B. An extensive surgical debridement was performed until healthy 
bleeding bone was visualized. C. A chimeric ALT-Vastus lateralis flap was harvested 
for reconstruction. D. Six months post-operative result.  
wound dehiscence in one case (20%) 
that required revision surgery. All flaps 
survived completely. All patients re-
sumed oral diet one week after last sur-
gical procedure. 
Diagnosis of BRONJ was histologically 
confirmed in all cases. 
After a mean follow-up of 13 months, no 
clinical or radiographic evidence of recur-
rent BRONJ was evident in any patients. 
No patient complained about deficits in 
quadriceps strength affecting his/her 
daily life. 
 
Discussion 
Our case series shows that aggressive 
debridement and reconstruction with chi-
meric ALT-Vastus lateralis flap is an ef-
fective option for the treatment of pa-
tients with a stage III BRONJ of the max-
illa. 
Recent literature recommends conserva-
tive treatment for BRONJ in the early 
stages, and more aggressive treatment 
for advanced disease3,13-15. Moreover, in 
a recent report Rupen et al. advocate 
that extensive surgery ensures better 
outcomes compared with conservative 
surgery, irrespective of the BRONJ stage, 
and not only in advanced stages 16.  
In our series, aggressive debridement 
was performed in all patients up to visu-
alization of healthy bleeding bone. Cold 
instruments were used for this purpose, 
to avoid bone damage from the high 
temperature developed by high-energy 
drills and saws. 
All patients received antibiotic treatment 
from one hour before surgery to 15 days 
post-operative, as we considered the 
bone infected by definition, given a stage 
III BRONJ diagnosis. In fact, several au-
thors17-19 suggest a constant role of in-
fection in the clinical course of this dis-
ease. 
Many reconstructive options have been 
proposed following sequestrectomy, in-
cluding local flaps, bone grafts and vas-
cularized bone-free flaps13,20. However, 
no treatment has been recognized as the 
gold standard so far. 
Differently from other head and neck re-
gions21,22, traditional, perforator or pro-
peller local flaps are not recommended, 
as they do not allow for the filling of the 
dead space left by bone resection. Also, 
the mucosa surrounding the osteonecro-
sis area is often unstable and prone to 
ulcerations and infections. 
The use of bone reconstruction is still de-
bated4,13,20. Bone grafts are biologically 
inert and do not supply the vascular sup-
port needed in a hypovascular bone. Re-
cent reports on bone reconstruction with 
a fibula free flap are promising and sug-
gest that it is a safe and effective proce-
dure in BRONJ patients. Literature on this 
topic is still limited, and larger series are 
required to validate application on a large 
clinical scale20,23,24. Despite being gener-
ally accepted that axial and appendicular 
bones are less susceptible to bisphospho-
nates, concerns still remain about the 
risk of transferring a bone that is not 
completely “healthy” 25, especially in 
cases of multiple mieloma. However, in 
spite of this, there are the successful re-
ports of bone reconstruction in these pa-
tients that, despite rigid fixations do per-
form well12,20,23. Also, the use of implants 
requires good coverage (local tissues are 
often inadequate for this purpose) and 
exposes the patient to a higher infection 
risk (on an already contaminated field)17-
19. 
For these reasons, we do recommend re-
construction with a distant well-
vascularized, soft tissue flap. We believe 
that the chimeric ALT-Vastus lateralis flap 
is a valuable option for stage III BRONJ 
of the maxilla, as the muscle part of the 
flap provides a good vascular supply and 
enough tissue to fill the dead space, 
while the skin allows for intraoral resur-
facing. Also, the versatility of ALT-Vastus 
lateralis flap in the head and neck region 
has already been demonstrated by sev-
eral authors26-30. As for other head and 
neck defects, the mobility between skin 
and muscle allows for a customized three
-dimensional reconstruction in patients 
affected by BRONJ.  
The limit of this technique is that it does 
not follow the principle of a “like-with-
like” reconstruction, and it fills a defect 
but does not restore functionality. This is 
why we do recommend the technique 
only for reconstruction of the maxilla, 
and not of the mandible, where the func-
tional unrepaired deficit would be more 
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evident. Considering the uneventful heal-
ing, the early resumption of oral diet, 
and the absence of recurrent disease, we 
believe that the advantages of this thera-
peutic option justify the residual func-
tional deficit in patients with a maxillary 
localization who are not candidates for 
prosthetic rehabilitation: patients in our 
series were weakened cancer patients 
with limited life expectancy, for which 
the main indications for surgery were 
pain and foul smelling discharge. For pa-
tients with mandibular localization, how-
ever, bone reconstruction should be con-
sidered more deeply, as significant man-
dibular deviation and difficulties with 
chewing arise if mandible stabilization/
reconstruction is not performed.  
Donor site morbidity is limited by the 
small amount of muscle usually required 
for reconstruction.  
Altogether, our data suggest that ag-
gressive debridement and reconstruction 
with a chimeric ALT-Vastus lateralis flap 
is an effective option for the treatment of 
stage III BRONJ of the maxilla. A limita-
tion of our study is the small sample 
size; larger and comparative clinical 
studies are desirable to compare tech-
niques and establish clinical guidelines. 
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